ALLK News and Press, Allakos Inc. From 05/08/19

REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019. First Quarter 20...

-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif., May 07, 2019 (GLOBE...

Allakos (NASDAQ: ALLK ): Q4 GAAP EPS of -$0.35 misses by $0.04. More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

REDWOOD CITY, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018, ...

REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive multiple dose Phase 1 results in patients with indolent systemic mastocytosi...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. All eyes will be on Bentonville, Arkansas this week with Walmart (WMT) due to relea...

Noteworthy events during the week of February 17 - 23 for healthcare investors. More news on: Allakos, Stemline Therapeutics, Aimmune Therapeutics, Healthcare stocks news, , Read more ...

An open-label Phase 2 clinical trial evaluating Allakos' (NASDAQ: ALLK ) lead drug AK002 in 11 patients with chronic spontaneous urticaria (hives) who failed to respond to Roche and Novartis' Xolair (omalizumab) after an average of 10 months' treatment showed a positive effect . More news...

-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients -- -- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU patients -- -- 54% (7/13) complete itch response by ISS7 in Xolair Naïve...